TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7948961
Drug: C1T (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1T (1 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Study: 3361022
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/kg/day during the first 3 days
Study: 31915047
Drug: Direct oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Direct oxytocin injection
Study: 11898510
Drug: Triptans (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptans (specific dosage and duration not mentioned)
Study: 8037261
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium lactate infusion
Study: 23030252
Drug: Pilocarpine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (10 mg)
Study: 19216936
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg, i.e., two sticks of Stay Alert gum) administered at 0100, 0300, 0500, and 0700 during nights 2, 3, and 4
Study: 19216936
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the same times as caffeine
Study: 11881131
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg once-daily for four weeks, titrated to 80 mg if necessary
Study: 11881131
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg once-daily for four weeks, titrated to 20 mg if necessary
Study: 9663917
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (n=16)
Study: 2687135
Drug: Proteolytic enzymes
Normalized name: Proteolytic enzymes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteolytic enzymes administered endotracheally in pre- and postoperative periods
Study: 31851093
Drug: 10-day dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day dual therapy (esomeprazole 20 mg and amoxicillin 750 mg, q.i.d.)
Study: 31851093
Drug: 14-day dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day dual therapy (esomeprazole 20 mg and amoxicillin 1000 mg, t.i.d.)
Study: 19104814
Drug: Capecitabine (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2,000 mg/(m(2) day) on days 1-14) and Irinotecan (250 mg/m(2) every 3 weeks)
Study: 7852519
Drug: hGH replacement
Normalized name: hGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH replacement therapy (12.5 micrograms/kg BW, self-administered daily sc)
Study: 2094113
Drug: Etofenamate 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate 10% cream
Study: 728318
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation of (+)-norpseudoephedrine and senna
Study: 28225674
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg
Study: 28225674
Drug: Lanadelumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 400 mg
Study: 21898496
Drug: sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 800 mg/day
Study: 21898496
Drug: sorafenib half
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib half dose
Study: 31391334
Drug: sorafenib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib therapy
Study: 20015433
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese herbal medicine plus conventional treatment
Study: 16467013
Drug: Physician characteristics
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician characteristics (e.g., professional orientation, location, and experience)
Study: 16467013
Drug: Patient factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient factors (e.g., contact with drug subculture, appearance, employment status, social support, having children)
Study: 9353692
Drug: Doxacurium administered
Normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxacurium administered by bolus injection
Study: 9353692
Drug: Doxacurium administered
Normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxacurium administered by 10-min infusion
Study: 9353692
Drug: Doxacurium with
Normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxacurium with Rtot model (infusion)
Study: 6393937
Drug: Rectal metronidazole
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal metronidazole
Study: 28554530
Drug: Electrical Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Muscle Stimulation (EMS) treatment, 3 times over a period of 1 week, 1-hour sessions each.
Study: 28554530
Drug: Electrical Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Muscle Stimulation (EMS) treatment
Study: 26424212
Drug: SUA quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUA quartile III (281-420 mmol/L)
Study: 26424212
Drug: SUA quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUA quartile IV (420-1640 mmol/L)
Study: 23865335
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of oxaprozin enteric coated tablets (0.4 g)
Study: 23865335
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of oxaprozin enteric coated tablets (0.4 g)
Study: 21547496
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg (n=26)
Study: 19002650
Drug: Sertraline usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline usual formulation
Study: 19002650
Drug: Sertraline liquid
Normalized name: sertraline Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline liquid oral concentrate (LOC) formulation
Study: 15964100
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 or 40 IU)
Study: 11461738
Drug: Propranolol (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1.6 mg/kg/day)
Study: 8091754
Drug: Live cold-adapted
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold-adapted attenuated vaccine
Study: 8091754
Drug: Whole-virus inactivated
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus inactivated trivalent vaccine
Study: 8091754
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines (including live and inactivated)
Study: 8091754
Drug: Revaccinated children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccinated children with preexisting antibody
Study: 28871961
Drug: Vaccine strains
Normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine strains
Study: 29231342
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling pretreatment (once a day) at specific acupuncture points for three months before embryo transfer, along with antibiotics and oral progesterone after ovulation.
Study: 29231342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with antibiotics in the menstrual period and oral progesterone after ovulation.
Study: 25925226
Drug: HOME Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOME Plus intervention (community-based program with ten monthly sessions and five motivational calls)
Study: 18551819
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA morphine only (Morphine PCA group, n = 90)
Study: 18551819
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA morphine only (Morphine PCA group)
Study: 16520410
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of ginseng for 12 weeks
Study: 12775894
Drug: Emla cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emla cream
Study: 10551577
Drug: Ropivacaine (0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.25%, 1 ml/kg)
Study: 10551577
Drug: Bupivacaine (0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25%, 1 ml/kg)
Study: 1860289
Drug: Malarial chemoprophylaxis
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malarial chemoprophylaxis (300 mg chloroquine weekly for at least one year)
Study: 31123090
Drug: Bedsheet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedsheet and intravenous pole
Study: 18715524
Drug: Rivaroxaban 50
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 50 mg
Study: 16423208
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin therapy
Study: 16423208
Drug: Intravenous OK432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous OK432 therapy
Study: 16423208
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cisplatin and OK432
Study: 15052382
Drug: Methylprednisolone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1000 mg i.v.)
Study: 15052382
Drug: Sivelestat (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.20 mg/kg per h)
Study: 15052382
Drug: Immunoglobulin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (5 g for 3 days)
Study: 15052382
Drug: Sivelestat (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.004 mg/kg per h)
Study: 8823657
Drug: FEV1 residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEV1 residual less than -1.2 L (optimal cut-off)
Study: 6380858
Drug: Once-daily metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily metoprolol (Betaloc tablets)
Study: 6380858
Drug: Twice-daily metoprolol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily metoprolol (Betaloc Durules)
Study: 3524185
Drug: Potassium-sparing diuretic
Normalized name: Potassium-sparing diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretic amiloride
Study: 29759656
Drug: Emergency medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medicine residency training
Study: 27929346
Drug: d-amphetamine 1
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 1 mg
Study: 27929346
Drug: d-amphetamine 2
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 2 mg
Study: 25045832
Drug: Probiotic-enriched foods
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-enriched foods or dietary supplement containing SYNBIO®
Study: 20810998
Drug: Donepezil (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (maximum 10 mg per day)
Study: 19075497
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid at 1 mg/day
Study: 10232867
Drug: Daily averages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily averages of symptoms
Study: 10232867
Drug: Weekly averages
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly averages of symptoms
Study: 10232867
Drug: 2-week intervals
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week intervals during treatment
Study: 1925430
Drug: Individually planned
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individually planned energy-restricted diet of 1000-1500 kcal per day, weekly discussions, and various leaflets on diet modification and increase of physical activity
Study: 6660028
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (20 g X 4/day)
Study: 6660028
Drug: Haemodialysis (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodialysis (3 treatments of 5 hours each)
Study: 28957643
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg tiotropium Respimat
Study: 28957643
Drug: 18 μg
Normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 μg HandiHaler
Study: 22472154
Drug: morphine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.05 mg/kg) IV during gallbladder extraction and (0.15 mg/kg) for 40 min postoperatively
Study: 22472154
Drug: ketorolac (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac (0.2 mg/kg) IV during gallbladder extraction and (0.7 mg/kg) for 40 min postoperatively
Study: 20353029
Drug: Modified Huanglian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Huanglian Wendan Decoction (HWD) 200 mL, twice a day
Study: 20353029
Drug: Aniracetam 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aniracetam 0.2 g (0.1 g for patients over 70), three times a day
Study: 16107896
Drug: AML-92/94 protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML-92/94 protocol (modified BFM-93) without maintenance therapy and prophylactic cranial irradiation
Study: 11810342
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (8 group sessions)
Study: 9231815
Drug: ET-1 infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 infusion (0.5 ng/kg per minute for 60 minutes, then 1.0 ng/kg per minute for 60 minutes, and finally 2.0 ng/kg per minute for 60 minutes)
Study: 8186511
Drug: L-phenylalanine (L-Phe)
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine (L-Phe) plus UVA irradiation
Study: 8186511
Drug: Increased L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased L-phenylalanine dose
Study: 8186511
Drug: Optimal L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal L-phenylalanine dose
Study: 25423323
Drug: Bilateral salpingo-oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral salpingo-oophorectomy (BSO) without subsequent hormone therapy (HT)
Study: 22722891
Drug: Almond diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond diet (56 g/day, replacing 20% of total daily calorie intake)
Study: 7959144
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (2%)
Study: 27686943
Drug: Temozolomide chemotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days for 12 cycles)
Study: 19929975
Drug: AZ-ER (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ-ER (single oral 2-g dose)
Study: 19929975
Drug: AZ-IR (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ-IR (3 days, 500 mg once daily)
Study: 16387893
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g i.v. carnitine
Study: 12243707
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole 600 mg/day for adults and 10 mg/kg per day for children for 30 days
Study: 12243707
Drug: Intra-lesional meglumine
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-lesional meglumine antimoniate (Glucantime) with 6-8 biweekly injections
Study: 7900613
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (even infrequent)
Study: 2670331
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (50%), insulin (80 units/I), and potassium (100 meq/l) (GIK) infused at a rate of 1 ml/kg/hr for up to 48 hours
Study: 31189511
Drug: Dulaglutide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (1.5 mg weekly subcutaneous injection)
Study: 17950093
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous insulin infusion (3 one-hour courses per week)
Study: 17950093
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (3-4 injections per day)
Study: 17950093
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous insulin infusion
Study: 16342005
Drug: Lithium serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium serum levels > 0.5 meq/l
Study: 11928799
Drug: 5‐fluorouracil (5‐FU)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU)‐based chemotherapy
Study: 9456255
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement with arginine and omega-3 fatty acids
Study: 9456255
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement without arginine and omega-3 fatty acids (Control)
Study: 28391912
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day for 4 weeks then 20 mg/day for 16 weeks
Study: 21719555
Drug: Darbepoetin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoetin (60 μg/injection)
Study: 17711731
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Propofol 2 microg/ml and Rimifentanil 2 ng/ml with fluid expansion of Hetastarch 5 ml/kg
Study: 17711731
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (Control): Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Study: 17711731
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Study: 7788917
Drug: Low-dose isoproterenol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoproterenol infusion during tilt testing at 60 degrees
Study: 7788917
Drug: Low-dose isoproterenol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoproterenol infusion during tilt testing at 70 degrees
Study: 7788917
Drug: Low-dose isoproterenol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoproterenol infusion during tilt testing at 80 degrees
Study: 7788917
Drug: Tilt testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt testing at 70 degrees with 1.5 micrograms/min isoproterenol infusion
Study: 7788917
Drug: Tilt testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt testing at 70 degrees with 3 micrograms/min isoproterenol infusion
Study: 7788917
Drug: Tilt testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt testing at 70 degrees with 5 micrograms/min isoproterenol infusion
Study: 7788917
Drug: Tilt testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt testing during 3 micrograms/min isoproterenol infusion
Study: 7788917
Drug: Tilt testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt testing during 5 micrograms/min isoproterenol infusion
Study: 1098155
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mebendazole twice a day for three days
Study: 1098155
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mebendazole twice a day for four days
Study: 28246206
Drug: gemcitabine/simtuzumab 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine/simtuzumab 700 mg
Study: 28246206
Drug: gemcitabine/simtuzumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine/simtuzumab 200 mg
Study: 26939315
Drug: Acupuncture (Tianshu,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (Tianshu, Zusanli, Shangjuxu, Taichong, Sanyinjiao, Yintang, Baihui), once a day, 5 treatments a week for 4 weeks.
Study: 26939315
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral solution, 15 mL three times a day for 4 weeks.
Study: 26939315
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral solution (same as above)
Study: 23936893
Drug: Distressed preneedle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distressed preneedle toddlers (regardless of treatment group)
Study: 18430242
Drug: Subgrouping using
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgrouping using a novel tool combined with targeted treatment delivered by trained physiotherapists
Study: 12930428
Drug: Adjuvant intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravesical sequential bacillus Calmette‐Guérin (BCG) and epirubicin
Study: 12930428
Drug: Epirubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (50 or 80 mg)
Study: 12930428
Drug: Adriamycin 50
Normalized name: ADRIAMYCIN 50 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin 50 mg